Harmony Biosciences receives FDA approval for Wakix for pediatric cataplexy

Harmony Biosciences (HRMY) announced that the U.S. Food and Drug Administration has approved its supplemental new drug application for Wakix tablets for the treatment of cataplexy in pediatric patients six years of age and older with narcolepsy. Wakix is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy.